Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
ESMO Open
|
December 5, 2021
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R Kanesvaran, C Porta, A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
R J Motzer, L Albiges, S A Treviño Aguirre, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open
|
August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
M S van der Heijden, T Powles, S Gupta, et al.
Oncogene
|
March 3, 2015
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair
N Kanu, E Grönroos, P Martinez, et al.
ESMO Open
|
July 10, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
S Peters, M-L Meyer, F André, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
R J Motzer, B Escudier, M Burotto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
ESMO Open
|
December 5, 2021
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R Kanesvaran, C Porta, A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
R J Motzer, L Albiges, S A Treviño Aguirre, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open
|
August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
M S van der Heijden, T Powles, S Gupta, et al.
Oncogene
|
March 3, 2015
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair
N Kanu, E Grönroos, P Martinez, et al.
ESMO Open
|
July 10, 2026
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
S Peters, M-L Meyer, F André, et al.
Page
of 9